Search results for "MUSCLE PROTEIN-SYNTHESIS"

showing 2 items of 2 documents

Effects of Leucine Administration in Sarcopenia: A Randomized and Placebo-controlled Clinical Trial

2020

Treating sarcopenia in older individuals remains a challenge, and nutritional interventions present promising approaches in individuals that perform limited physical exercise. We assessed the efficacy of leucine administration to evaluate whether the regular intake of this essential amino acid can improve muscle mass, muscle strength and functional performance and respiratory muscle function in institutionalized older individuals. The study was a placebo-controlled, randomized, double-blind design in fifty participants aged 65 and over (ClinicalTrials.gov identifier NCT03831399). The participants were randomized to a parallel group intervention of 13 weeks&rsquo

Malemedicine.medical_specialtyBODY-COMPOSITIONrespiratory muscles030209 endocrinology & metabolismPhysical exerciselcsh:TX341-641MASSPlaceboOBSTRUCTIVE PULMONARY-DISEASEelderlyArticlesarcopenia03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineDouble-Blind MethodLeucineInternal medicineSTRENGTHRespiratory musclemedicineMUSCLE PROTEIN-SYNTHESISHumansAMINO-ACIDS030212 general & internal medicineVITAMIN-D SUPPLEMENTATIONEssential amino acidAgedchemistry.chemical_classificationAged 80 and overNutrition and Dieteticsbusiness.industryWHEY-PROTEINmedicine.diseaseClinical trialnutritionchemistrymuscle massSarcopeniaLean body massmuscle strengthFemaleLeucinePHYSICAL PERFORMANCEbusinesslcsh:Nutrition. Foods and food supplyFood ScienceNutrients
researchProduct

Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy

2017

Background: Inhibition of activin/myostatin pathway has emerged as a novel approach to increase muscle mass and bone strength. Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that leads to progressive muscle degeneration and also high incidence of fractures. The aim of our study was to test whether inhibition of activin receptor IIB ligands with or without exercise could improve bone strength in the mdx mouse model for DMD. Methods: Thirty-two mdx mice were divided to running and non-running groups and to receive either PBS control or soluble activin type IIB-receptor (ActRIIB-Fc) once weekly for 7 weeks. Results: Treatment of mdx mice with ActRIIB-Fc resulted in significantly…

bone-muscle interactionsOXIDATIVE CAPACITYMDX MICEbone μCTexerciseBLOCKINGBone mu CTEXERCISEPREVENTS3126 Surgery anesthesiology intensive care radiologyMYOSTATINBone-muscle interactionsanimal modelsAnimal modelsDEFICIENCYTGF-βsDENSITY3121 General medicine internal medicine and other clinical medicineMUSCLE PROTEIN-SYNTHESISOrthopedics and Sports MedicineTGF-beta sMETAANALYSIS
researchProduct